Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Bank of New York Mellon Corp grew its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 4.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 127,093 shares of the company’s stock after buying an additional 5,448 shares during the period. Bank of New York Mellon Corp owned 0.20% of Kymera Therapeutics worth $5,113,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Massachusetts Financial Services Co. MA increased its position in Kymera Therapeutics by 11.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock worth $21,458,000 after purchasing an additional 47,507 shares during the period. Eventide Asset Management LLC boosted its stake in shares of Kymera Therapeutics by 9.9% in the 3rd quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock valued at $24,039,000 after purchasing an additional 45,803 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Kymera Therapeutics during the 3rd quarter worth approximately $650,000. JPMorgan Chase & Co. raised its stake in shares of Kymera Therapeutics by 212.6% during the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock worth $6,649,000 after buying an additional 95,547 shares during the last quarter. Finally, Natixis Advisors LLC acquired a new position in Kymera Therapeutics in the third quarter valued at approximately $681,000.

Analysts Set New Price Targets

Several analysts have commented on KYMR shares. BMO Capital Markets started coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 target price for the company. BTIG Research assumed coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective for the company. HC Wainwright raised their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. Finally, Stephens reissued an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.36.

Insiders Place Their Bets

In other Kymera Therapeutics news, insider Ellen Chiniara sold 2,241 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the transaction, the insider now directly owns 80,085 shares in the company, valued at $2,438,588.25. This trade represents a 2.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,788 shares of company stock valued at $455,202 in the last three months. 15.82% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $34.49 on Tuesday. The stock has a 50-day simple moving average of $37.32 and a 200 day simple moving average of $42.66. Kymera Therapeutics, Inc. has a 52-week low of $29.07 and a 52-week high of $53.27. The company has a market cap of $2.24 billion, a PE ratio of -14.74 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. On average, research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.